

EXHIBIT 1a

INTERNATIONAL PATENT COOPERATION TREATY

PCT

Received: April 11, 2001

WIPO

PCT

PRELIMINARY INTERNATIONAL EXAMINATION REPORT

(Article 36 and Rule 70 of the PCT)

Applicant or Attorney File No. H 3939 PCT	FURTHER PROCEDURE See Bulletin on the Transmission of the Preliminary International Examination Report (Form PCT/IPEA/416).	
International File No. PCT/EP00/08773	International Application Date (Month/Day/Year) September 8, 2000	Priority Date (Month/Day/Year) September 17, 1999
International Patent Classification (IPC) or National Classification and IPC A61K7/13		
Applicant HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN		

1. This preliminary international examination report was prepared by the office assigned to perform the preliminary international examination and is being transmitted to the applicant in accordance with Article 36.
2. This REPORT consists of a total of 4 pages, including this cover page.
 - o In addition, the report also includes ATTACHMENTS. These are pages with descriptions, claims, and/or drawings which were revised and which served as a basis for the present report and/or pages with corrections made before this a representative of this office (see Rule 70.16 and Section 607 of the Administrative Guidelines of the PCT).

These attachments consist of a total of pages.

EPO - DG 1**August 24, 2001**

3. This report contains information on the following points:

- | | | |
|------|-------------------------------------|---|
| I | <input checked="" type="checkbox"/> | Basis of the report |
| II | <input type="checkbox"/> | Priority |
| III | <input type="checkbox"/> | No evaluation issued on novelty, inventive activity, or commercial viability |
| IV | <input type="checkbox"/> | Invention deficient with respect to uniformity |
| V | <input checked="" type="checkbox"/> | Substantiated determination according to Article 35(2) concerning novelty, inventive activity, and commercial viability; documents and explanations in support of this determination. |
| VI | <input type="checkbox"/> | Specific cited documents |
| VII | <input checked="" type="checkbox"/> | Specific defects in the international application |
| VIII | <input type="checkbox"/> | Specific remarks concerning the international application |

Filing Date of the Request: February 2, 2001	Report Completion Date: April 6, 2001
Name and mailing address of the office assigned to perform the preliminary examination: European Patent Office D-80298 Munich Tel: +49 89 2399-0 Telex: 523658 epmu d Fax: +49 89 2399-4465	Authorized Official: Drew, C Tel: +49 89 2399 8494

Form PCT/IPEA/409 (Cover Page) (January 1994)

**PRELIMINARY INTERNATIONAL
EXAMINATION REPORT**International File No.: **PCT/EP00/08773****1. Basis of the Report**

1. With respect to the **components** of the international application (*replacement pages which were submitted to the application office in compliance with the request according to Article 14 are considered "originally filed" and are not attached to the application, because they do not contain any changes (Rules 70.16 and 70.17)*):
- Specification, pages:**

1-21 original version

Claims, Nos.:

1-18 original version

2. With respect to the **language**: Unless otherwise indicated under this point, all of the components cited above were available to the Office in the language in which the international application was filed or were submitted in this language.

The components were available to the Office or submitted in the language:

The language in question is:

- ☐ the language of the translation which was submitted for the purpose of the international search (according to Rule 23.1(b))
 - ☐ the publication language of the international application (according to Rule 48.3(b)).
 - ☐ the language of the translation which was submitted for the purpose of the preliminary international examination (according to Rule 55.2 and/or Rule 55.3).
3. With respect to the **nucleotide and/or amino acid sequence** disclosed in the international application, the preliminary international examination has been completed on the basis of the sequence protocol which:
- ☐ is contained in written form in the international application.
 - ☐ was submitted in computer-readable form together with the international application.
 - ☐ was submitted in written form to the Office.
 - ☐ was submitted in computer-readable form to the Office.
 - ☐ The declaration that the subsequently submitted written sequence protocol does not exceed the disclosure content of the international application at the time of the application was presented.
 - ☐ The declaration that the information recorded in computer-readable form is the same as the written sequence protocol was presented.

4. As a result of the changes, the following documents are eliminated:

- ☐ Specification, pages:
☐ Claims, Nos.:
☐ Drawings, sheet:

5. ☐ This report has been prepared without consideration (of some) of the changes, because the Office believes, for the reasons given, that these changes go beyond the disclosure content of the originally filed version (Rule 70.2(c)).

(Reference to replacement pages which contain such changes is to be made under Section 1; they are to be attached to this report.)

6. Any additional remarks.

V. Substantiated determination according to Article 35(2) with respect to novelty, inventive activity, and commercial viability; documents and declarations in support of this determination.

1. Determination

Novelty (N)	Yes:	Claims 1-18
	No:	Claims
Inventive Activity (AI):	Yes:	Claims 1-18
	No:	Claims
Commercial Viability (CV).	Yes:	Claims 1-18
	No:	Claims

2. Documents and Declarations
See attached page.

VII. Specific defects in the international application

It was determined that the international application has the following defects with respect to form or content:
See attached page.

**PRELIMINARY INTERNATIONAL
EXAMINATION REPORT**International File No.: **PCT/EP00/08773**

Part V

1. GB-A-1,349,118, cited in the international search report, describes the use of 1-(N-hydroxyethylamino)-2-nitro-4-aminobenzenes in hair coloring and hair conditioning agents for shifting the nuances into the red region; it also describes the corresponding agents. It is impossible to find in the state of the art any suggestion, however, that these compounds can be replaced by 1-(N-cyclopentylamino)-2-nitro-4-aminobenzenes. Claims 1-18 are thus probably novel and inventive as defined in Article 33, Sections (2) and (3) of the PCT

Part VII

2. GB-A-1,349,118 is not acknowledged in the present specification, Rule 5.1(a)(ii) of the PCT.